OSI Pharma (OSIP) Partner Genetech Reports Positive Tarceva Data For Lung Cancer
More News related to OSIP
- OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd
- OSI Pharma (OSIP) volume and volatility increases into Tarceva committee review
- ODAC to Review Using OSI Pharma's (OSIP) Tarceva as First-Line Therapy for Patients with Advanced Non-Small Cell Lung Cancer
- OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
- OSI Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009
More News related to FDA
- Protalix (PLX) Sells-Off On Pfizer News, As Fast Money Disappointed In No Takeover
- Masimo (MASI) Receives FDA Clearance for Rainbow SET Acoustic Monitoring
- Protalix (PLX) Enters Deal With Pfizer (PFE) To Develop Gaucher's Disease Treatment
- Human Genome (HGSI) Raises Money As It Gears Up for Benlysta Approval
- Human Genome Sciences (HGSI) To Offer Up to 12.5M Shares
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that its U.S. partner for Tarceva, Genentech, Inc., a wholly-owned member of the Roche Group, informed OSI of detailed results from a Genentech conducted Phase III study (ATLAS). The study met its primary endpoint by demonstrating that patients with advanced non-small cell lung cancer (NSCLC) who received Tarceva in combination with Avastin as first-line maintenance treatment had a 39 percent improvement in the time they lived without the disease worsening (progression-free survival or PFS), compared with those who received Avastin plus placebo as an active control (hazard ratio=0.72; p=0.0012; a hazard ratio of less than one indicates a decreased risk of disease progression and a p-value of less than 0.05 indicates statistical significance).
Adverse events were consistent with previous Avastin or Tarceva NSCLC studies, or trials evaluating the two medicines together.
Genentech also informed OSI that median PFS following four initial cycles of Avastin and chemotherapy was 4.8 months for patients who received the combination and 3.7 months for those who received Avastin plus placebo. Overall survival data are expected in the second half of 2009. In February 2009, it was announced that ATLAS was stopped early on the recommendation of an independent data safety monitoring board after a pre-planned interim analysis showed that combining Tarceva and Avastin significantly extended PFS, compared with Avastin plus placebo.
Results of the ATLAS study were featured at ASCO.
More from Release
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
